<DOC>
	<DOCNO>NCT00217555</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine topotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together topotecan work treat patient recurrent persistent ovarian , fallopian tube , primary peritoneal cavity cancer .</brief_summary>
	<brief_title>Gemcitabine Topotecan Treating Patients With Recurrent Persistent Ovarian , Fallopian Tube , Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine nature degree toxicity gemcitabine topotecan patient recurrent persistent platinum-refractory ovarian , fallopian tube , primary peritoneal cavity cancer . - Determine response rate patient treat regimen . - Determine quality life patient treat regimen . Secondary - Determine duration progression-free survival overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive gemcitabine IV 30 minute topotecan IV 30 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 2 additional course beyond documentation CR . Quality life assess baseline , day 1 course 2 , 4 , 6 , 1 year . After completion study treatment , patient follow every 3 month 2 year every 6 month thereafter . PROJECTED ACCRUAL : Approximately 36-45 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis ovarian , fallopian tube , primary peritoneal cavity cancer Recurrent persistent platinumrefractory disease , define 1 following : Progressive disease platinum compound Persistent clinically measurable disease best response stable disease completion ≥ 6 course therapy Recurrent disease within 6 month completion therapy Measurable evaluable disease Evaluable disease , define CA 125 ≥ 100 U/mL ( confirm 2 blood test ) Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique , include palpation , plain xray , CT scan , MRI , OR ≥ 10 mm spiral CT scan PATIENT CHARACTERISTICS : Age 18 Performance status GOG 03 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) SGOT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Creatinine clearance &gt; 50 mL/min Other No clinically significant infection No severe medical condition would preclude study treatment No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix breast PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Prior gemcitabine topotecan allow provided disease refractory either drug At least 3 week since prior chemotherapy recover Endocrine therapy Not specify Radiotherapy At least 3 week since prior radiotherapy recover Surgery Recovered recent prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>